|
| Press Releases |
|
 |
|
| Thursday, October 30, 2025 |
|
|
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders |
| Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. ('Visara'), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol 'NBP'), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries. more info >> |
|
| Tuesday, October 14, 2025 |
|
|
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 |
| Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States. more info >> |
|
| Thursday, October 9, 2025 |
|
|
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology |
| Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatment of subjects with moderately to severely active ulcerative colitis (UC) have been published in the prestigious international journal The Lancet Gastroenterology & Hepatology, marking the global recognition of this next-generation selective S1P receptor modulator's efficacy in Asian patients. more info >> |
|
| Monday, September 1, 2025 |
|
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D |
| Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company's total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. more info >> |
|
| Friday, August 15, 2025 |
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC |
| Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the 'Updated Guidelines'). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence. more info >> |
|
| Thursday, August 14, 2025 |
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access |
| Everest Medicines (HKEX 1952.HK, 'Everest') today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY' (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). more info >> |
|
| Friday, August 8, 2025 |
|
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan |
| Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON'. more info >> |
|
| Tuesday, August 5, 2025 |
|
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts |
| Everest Medicines (HKEX 1952.HK) today announced that the supplemental application for the production expansion of NEFECON has been officially approved by China's National Medical Products Administration (NMPA). more info >> |
|
| Saturday, August 2, 2025 |
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies |
| Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. more info >> |
|
| Friday, July 25, 2025 |
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
| Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The University of Osaka D3 Center and NEC Demonstrate Wide-Area Distributed Campus AI Processing Platform
Nov 13, 2025 0:41 JST
|
|
|
Toyota to Invest Up to $10 Billion Additional in Its U.S. Operations Over the Next Five Years
Nov 13, 2025 0:08 JST
|
|
|
MHI Thermal Systems Launches Magnetic Bearing Centrifugal Chiller "ETI-N" Series for Japanese Market
Nov 13, 2025 23:34 JST
|
|
|
MHI Completes Joint Demonstration with Kirin Group for Automation of Warehouse Operations, and Truck Loading and Unloading
Nov 13, 2025 23:00 JST
|
|
|
Kraft Heinz and OMP Showcase Smarter, More Sustainable Value Chain at Gartner Supply Chain Planning Summit
Nov 13, 2025 22:00 HKT/SGT
|
|
|
Between Clouds and Sea: Discovering the Beauty of Taiwan's Caoling Historic Trail 
Nov 13, 2025 20:00 HKT/SGT
|
|
|
Research findings confirm Hong Kong's continued 'superconnector' role in global and regional supply chain transformation
Nov 13, 2025 17:24 HKT/SGT
|
|
|
Dynasty Wins Two Silver and One Bronze Medals at 2025 GWSAA
Nov 13, 2025 16:37 HKT/SGT
|
|
|
JCB launches second round of Shopping Mall Shuttle Free Ride Campaign in Guam
Nov 13, 2025 11:00 JST
|
|
|
Bermuda-Regulated Chainproof Chooses Blockpass to Power KYB for Smart Contract, Slashing, and Yield Insurance
Nov 13, 2025 04:00 HKT/SGT
|
|
|
NTT, NTT DOCOMO Establish the Large Action Model (LAM), an AI Technology to Accelerate 1-to-1 Marketing
Nov 12, 2025 19:00 JST
|
|
|
Mitsubishi Power Receives Second H-25 Gas Turbine Order for Chang Chun Petrochemical's Miaoli Factory in Taiwan
Nov 12, 2025 18:43 JST
|
|
|
Italian businesses eye Hong Kong as key gateway to Asia
Nov 12, 2025 17:27 HKT/SGT
|
|
|
New Report Reveals Brazilians Face 252 Scam Encounters Annually Despite High Confidence in Spotting Fraud
Nov 12, 2025 17:20 HKT/SGT
|
|
|
All-New Delica Mini and eK Space Win RJC Car of the Year Award for 2026
Nov 12, 2025 18:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
